Impact of Acceptance and Commitment Therapy on Early Stage Breast Cancer
NCT ID: NCT01164930
Last Updated: 2021-10-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2010-01-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer
NCT00226928
An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain
NCT05374161
An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer
NCT03429907
The Long-term Effects of Body-mind-spirit Group Therapy
NCT01727635
A RCT of Psychosocial Interventions Facilitating Positive Psychological Adaptation in Breast Cancer
NCT06531135
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Traditional breast cancer groups, however, may not adequately address these areas because existing interventions often target the reduction of distress as the primary vehicle to improve psychosocial, quality of life, and biophysical outcomes. Acceptance and Commitment Therapy (ACT) is an empirically-supported, mindfulness-based psychological treatment that has been shown to enhance meaningful behavior change thorough increasing emotional acceptance of difficult psychological experiences such as distress, without the goal of changing or eliminating them.
The current study seeks to determine the preliminary effect of an 8-week ACT group in increasing positive life changes and corresponding increase in salivary cortisol slope in 40 distressed breast cancer patients, who will be randomly assigned to ACT or a wait list control group.
The hypotheses for the present study include:
* Patients receiving ACT will demonstrate improvements in Quality of Life (QoL), Benefit-finding (BF), and health behavior compared to control group participants
* ACT participants will demonstrate improvements in mean cortisol levels and cortisol reactivity compared to control group participants
* These changes will be the result of increased mindful acceptance of cancer-related distress and meaningful behavior changes, rather than a reduction in distress.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acceptance and Commitment Therapy group
8-week ACT group
Acceptance and Commitment Therapy
8-week ACT group
Wait-list control group
Participants will be offered treatment following wait-list data collection
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acceptance and Commitment Therapy
8-week ACT group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* prescreen distress score above defined cutoff
* agreement not to seek other breast cancer support services until study completion
Exclusion Criteria
* prior psychiatric treatment for serious mental health disorder (e.g., hospitalization or formal diagnosis of psychosis, major depressive episode, borderline mental retardation, suicidality, or current substance dependence)
* current use of medications known to interfere with cortisol levels (e.g., dexamethasone)
* major concurrent medical disease
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
San Jose State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jennifer A. Gregg, PhD
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Jose State University
San Jose, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.